Abstract：Objective：To observe the clinical effect of Fuzheng Qutan Jiedu tang combined with gefitinib tablets for nonsmall cell lung cancer(NSCLC) of qi deficiency and phlegm stasis type. Methods： A total of 114 cases of NSCLC patients treated in Chinese Medicine Hospital of Puyang were selected and divided into the control group and the observation group according to the random number table method， with 57 cases in each group. The control group was treated with gefitinib tablets， and the observation group was treated with Fuzheng Qutan Jiedu tang combined with gefitinib tablets. Chinese medicine syndrome scores， quality of life and immunity indexes before and after treatment in the two groups were compared；clinical effects and adverse reactions in the two groups were evaluated. Results：After treatment，the disease control rate in the observation group was significantly higher than that in the control group(P＜0.05). After treatment， the scores of Karnofsky Performance Status(KPS) and the levels of CD3+，CD4+ and NK cells in peripheral blood in the two groups were increased when compared with those before treatment，and the above indexes in the observation group were higher than those in the control group. After treatment，CD8 + levels in peripheral blood and Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment，and Chinese medicine syndrome score and CD8+ level in peripheral blood in the observation group were lower than those in the control group(P＜0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P＜0.05). Conclusion：The therapy of Fuzheng Qutan Jiedu tang combined with gefitinib tablets for NSCLC of qi deficiency and phlegm stasis type has a significant curative effect，and can significantly improve the immune function and quality of life of patients，and reduce the incidence of adverse reactions.